Long-Term Benefit for Recently Licensed Myasthenia Gravis Treatment.

Published Date: 18 Nov 2023

Up to 60 weeks of sustained benefit have been observed in early responders to zilucoplan, the recently approved medication for myasthenia gravis, according to new analyses.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cardiorespiratory fitness lowers the risk of colon, lung, and prostate cancer in MEN and lowers mortality from these diseases.

2.

Chemo causes lasting physical decline in breast cancer survivors

3.

VP Nominee Medical Records Breached; Queen Elizabeth's Cancer; Galaxy Gas Whippets

4.

Race, Geography Linked to Gaps in Prostate Cancer Care

5.

DNA origami offers more accurate imaging in the fight against pancreatic cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot